Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue

Pfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with relapsed or refractory disease who had ...